Background: Observational studies have demonstrated that de-escalation of antimicrobial therapy is 19 independently associated with lower mortality. This most probably results from confounding by 20 indication. Reaching clinical stability is associated with the decision to de-escalate and with survival.
Introduction

42
The aim of antimicrobial stewardship is improving antibiotic use, without compromising clinical outcomes 43 on the individual level (1) . De-escalation of empirical antimicrobial therapy is highly recommended in 44 antimicrobial stewardship programs. In a recent systematic review de-escalation of empirical
45
antimicrobial therapy was associated with a 56% (95% CI 34%-70%) relative risk reduction in mortality 46 (2) . Although it seems a safe strategy, most studies evaluating de-escalation and reporting mortality were observational with a high risk of bias and with high clinical heterogeneity. As it seems highly unlikely 48 that unnecessary broad-spectrum antibiotics lead to increased mortality in individual patients, the 49 association between de-escalation and improved survival in observational studies is most likely biased 
53
days after starting antimicrobial therapy and this also is a strong prognostic factor for patient outcome.
54
However, hardly any of the observational studies adjusts for clinical stability during admission. In the 55 aforementioned systematic review (2) only one of nineteen observational studies corrected for this 56 confounder (3) . Not taking this into account causes a negative bias (towards a protective effect).
57
However, the magnitude of this bias has never been established. The aim of the current study was to 58 quantify the potential effect of unmeasured confounding by indication (due to clinical stability) in the 59 association between de-escalation and patient outcome in patients with community-acquired 60 pneumonia.
Methods
Data were used from the Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA) (4 
70
For the current analysis, patients with a working diagnosis of CAP admitted to a non-intensive care unit
71
(ICU) and receiving antibiotics on the day of admission were included. Patients were excluded from the 72 current analysis if they participated in a simultaneously running interventional trial evaluating different
73
antibiotic regimens for CAP (5) , since this trial interfered with the choice of empirical antibiotic treatment,
74
or if they died within 24 hours of admission because these are not eligible for de-escalation.
76
Definitions
77
To define de-escalation, antibiotics were ranked based on their spectrum of activity against CAP 78 pathogens, from rank 1 ('narrow-spectrum') to rank 3 ('extended / restricted spectrum') antibiotics (Table   79 1). In patients with combination therapy, the highest rank of any individual antibiotic was counted, except 80 for combination therapy of β-lactam therapy and a macrolide, which was considered as rank 3, as for 81 respiratory pathogens this combination results in a much broader spectrum than any of the individual 82 antibiotics. Therapy adjustment was defined as the first switch from empirical therapy to another 83 antimicrobial class during hospitalization, independent of the reason for switching. De-escalation and 84 escalation were defined as a change to a lower rank or a higher rank, respectively. Continued regimens 85 or adjustments to an equivalent rank were defined as continuation. To quantify the effect of unmeasured confounding by indication we simulated clinical stability during hospital admission as a new confounder. We defined clinical stability during admission as a binary determinant (de-escalation), (2) the prevalence in group without the determinant (continuation) and (3) 111 the association with patient outcome (mortality). For the simulation of clinical stability at 72 hours we 112 reviewed the literature for reasonable assumptions for the three parameters.
113
We assumed that 80% of CAP patients admitted to a non-ICU ward will be clinically stable at day three,
114
based on three randomized controlled trials evaluating intravenous to oral switches in patients (6) (7) (8) . As 115 the prevalence of clinical stability in the total study population is a weighted average of the prevalence 116 of clinical stability in the de-escalation and the continuation group, the prevalence in one group can be 117 calculated from the prevalence in the other group. We assumed a high prevalence for clinical stability in 118 the de-escalation group, so we varied the prevalence from 80% to 100%, with corresponding calculated 119 prevalence's in the continued group between 80% and 75% to arrive at the overall prevalence of 80%.
120
The assumed crude odds ratio (OR) between clinical stability at 72 hours and 30-day mortality was 121 0.14, based on unpublished data of a randomized controlled trial evaluating the effect of adjunct 122 prednisone therapy versus placebo on time to clinical stability for patients with CAP (Courtesy of dr.
123
Blum) (9) . In this trial, clinical stability was measured every 12 hours during hospital stay and was defined 
165
Effect of confounding by indication due to clinical stability
166
The results of the simulation analysis are depicted in Figure 3 . Not using clinical stability for adjustment 
172
it was substantially stronger than any of the observed confounders in our dataset (Table 3) . 
233
However, de-escalation is performed on a different day for each individual and should be analyzed as a 234 time-dependent variable, otherwise it introduces immortal time bias (18) .
236
It is recommended to include sensitivity analyses to estimate the potential impact of unmeasured 237 confounding in every non-randomized study on causal associations (19) . However, for observational 238 studies evaluating de-escalation of antimicrobial therapy this has never been done before. To strengthen 239 our sensitivity analysis we based our assumptions about the prevalence of clinical stability and 240 association with mortality on existing high-quality data. We further assumed that physicians will only de-
241
escalate when a patient is clinically stable or to initiate targeted treatment for an identified pathogen. In 242 the latter case, we still expect that most patients in whom the physician decides to de-escalate will be clinically stable. We, therefore, expect that at least 90% and probably close to 100% of de-escalated Strengths of our study include the pragmatic approach of using prospectively collected data of a large 247 patient population treated with empiric antibiotics and a working diagnosis of CAP. This included patients 248 without an identified pathogen, which increases the generalizability of our study results. A limitation of 249 our study is that we had to make assumptions for the prevalence of clinical stability in the de-escalated
250
and continued group and for the association between clinical stability and day-30 mortality. These were
251
derived from different study populations, all representing CAP patients hospitalized to a non-ICU ward.
252
Our findings suggest that adjustment for clinical stability will result in a non-significant effect of de-253 escalation on mortality, which would be biologically plausible. Our findings also demonstrate that the 254 individual baseline confounders, as measured in our study, only had minor effects on patient outcome,
255
indicating that their correlation with clinical stability is rather weak. Another simplification in our analysis
256
was that we modelled clinical stability as a binary variable on day 3, which does not well represent reality.
257
For future studies we recommend to measure clinical stability repeatedly over time, as a time-varying 258 confounder and on a continuous scale. Finally, we did not have information on quality of our sputum 259 samples on which the pathogen was identified. Quality of sputum samples is also a prognostic factor for 260 de-escalation of empirical antimicrobial therapy, however we could not correct for this in our model.
262
The results of our analysis also indicate that clinically relevant harm due to de-escalation cannot be 
278
rather than improved outcome due to de-escalation (21 
287
escalation would be optimally studied in a pragmatic randomized controlled trial.
289
To conclude, the previously observed protective effect of de-escalation on mortality is likely due to
290
confounding by unobserved factors such as clinical stability during admission.
